Accuracy of Testing for Antibodies to Synthetic Gliadin–Related Peptides in Celiac Disease

Sugai, Emilia; Vázquez, Horacio; Nachman, Fabio; Moreno, María Laura; Mazure, Roberto M.; Smecuol, Edgardo; Niveloni, Sonia I.; Cabanne, Ana; Kogan, Zulema; Gómez, Juan Carlos

doi:10.1016/j.cgh.2006.05.004

Cited by 137 publications

(131 citation statements)

References 25 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…To sum up, our study confirms the preliminary data published by other authors, in which it is evident that AGA tests using deamidated gliadin peptides give excellent results in the diagnosis of CD patients (18,19,32). Our very heterogeneous case study demonstrates the particular diagnostic efficiency of the AGAs class IgG tests.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Diagnostic efficacy of the ELISA test for the detection of deamidated anti‐gliadin peptide antibodies in the diagnosis and monitoring of celiac disease

Tonutti

Visentini

Picierno

et al. 2009

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background and Aim: We evaluated the diagnostic performance of an ELISA test for anti-gliadin IgA and IgG antibodies, which uses synthetic deamidated gliadin peptides (anti-gliadin antibodies, AGAs) as coating; the results were compared with a test that uses extracted gliadin (AGAe). Methods: The study was conducted on the sera of 144 patients suffering from celiac disease (CD), including 20 patients with IgA deficiency and 9 who were following a gluten-free diet (GFD), and 129 controls. Results: In the 115 CD patients (without IgA deficiency), the sensitivity of AGAe IgA and IgG was 32.2 and 60.9%, whereas that of AGAs IgA and IgG was 59.1 and 72.2%. The specificity for AGAe IgA and IgG, and AGAs IgA and IgG was 93.8 and 89.9%, and 96.9% and 99.2%, respectively. Of the 20 patients with CD and IgA deficiency, 7 tested positive for AGAe IgG and 14 for AGAs IgG. The test using deamidated gliadin peptides performed better in terms of sensitivity and specificity than the AGA tests with extracted antigen. Conclusions: The very high specificity of the AGAs IgG test (99.2%) also suggests that patients who test positive with this assay require a thorough followup, even if the anti-tissue transglutaminase antibodies (anti-tTG) and anti-endomysial autoantibodies (EMA) assays are negative.

show abstract

Section: Discussionsupporting

confidence: 90%

“…These peptides have a relatively constant aminoacid pattern consisting of the sequence QPEQPFP, where the triplet PEQ is the epitopic core. Some studies demonstrate that immunoenzyme tests (ELISA) that use the sequence QPEQPFP as antigen have greater sensitivity and specificity than ELISA tests with extracted gliadin antigen (18,19).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic efficacy of the ELISA test for the detection of deamidated anti‐gliadin peptide antibodies in the diagnosis and monitoring of celiac disease

Tonutti

Visentini

Picierno

et al. 2009

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…The results of this study agree with this conclusion. However, IgA‐EMA as well as IgA‐tTG are regarded as both sensitive and specific markers for CD (Rostom et al., 2005; Sugai et al., 2006), and are presently used as standard screening tests. In contrast to this, Selva‐O'Callaghan et al.…”

Section: Discussionmentioning

confidence: 99%

“…Most patients (muscle biopsied 1997–2001) were also included in an earlier study, focusing on classification and the diagnostic gain of serial sectioning for diagnosing IIM (Danielsson, Lindvall, Gati, & Ernerudh, 2013). Four patients lacking gastrointestinal symptoms, whose sera showed raised levels of antibodies to AGA, declined a small bowel biopsy, and were, as an alternative, offered to be investigated for the presence of antibodies against antitissue transglutaminase (t‐TG), to increase the specificity for CD (Sugai et al., 2006). All sera were screened for IgA deficiency (i.e ., serum IgA <0.07 g/L).…”

Section: Methodsmentioning

confidence: 99%

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

et al. 2017

View full text Add to dashboard Cite

ObjectivesIdiopathic inflammatory myopathies (IIM) are often associated with other immune‐mediated diseases or malignancy. Some studies have reported a high frequency of celiac disease in IIM. The aim of this study was to investigate the prevalence of celiac disease, systemic inflammatory diseases, and malignancy in a cohort of IIM patients, and estimate the incidence of IIM in the county of Östergötland, Sweden.Material and MethodsWe reviewed medical records and analyzed sera from 106 patients, fulfilling pathological criteria of inflammatory myopathy, for the presence of IgA antibodies against endomysium and gliadin. Antibody‐positive patients were offered further investigation with small bowel biopsy or investigation for the presence of antibodies against antitissue transglutaminase (t‐TG). The patients were classified according to Bohan and Peter or Griggs criteria. The presence of celiac disease, systemic inflammatory, and malignant diseases was documented.ResultsFour of 88 patients classified as IIM (4.5%) had biopsy‐confirmed celiac disease, which is higher than the prevalence in the general population, detected with a similar screening procedure (0.53%). Thirty‐three patients (38%) had a systemic inflammatory disease and five (5.7%) a malignancy. The incidence of confirmed IIM in the county of Östergötland was 7.3 per million/year.ConclusionsThe results highlight the high frequency of associated inflammatory and malignant diseases and confirm an increased prevalence of celiac disease in IIM.

show abstract

“…DGP antibodies measured by ELISA came to be considered an additional or complementary serological tool in the diagnostic algorithm of CD [5,6]. In some studies, IgG DGPs had the highest sensitivity for the diagnosis of CD [6] in addition to potential diagnostic advantages over other antibodies [7].…”

mentioning

confidence: 99%

The CD That Pays Dividends: More Than 15 Years of Deamidated Gliadin Peptide Antibodies

Bai

Verdú

2017

Dig Dis Sci

View full text Add to dashboard Cite

Accuracy of Testing for Antibodies to Synthetic Gliadin–Related Peptides in Celiac Disease

Cited by 137 publications

References 25 publications

Diagnostic efficacy of the ELISA test for the detection of deamidated anti‐gliadin peptide antibodies in the diagnosis and monitoring of celiac disease

Diagnostic efficacy of the ELISA test for the detection of deamidated anti‐gliadin peptide antibodies in the diagnosis and monitoring of celiac disease

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

The CD That Pays Dividends: More Than 15 Years of Deamidated Gliadin Peptide Antibodies

Contact Info

Product

Resources

About